Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CK-0045 proof-of-concept study in overweight/obesity with type 2 diabetes
2024-514191-41-00Phase 2Completed
- Sponsor
- Cytoki Pharma
- Start
- Sep 2024
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and obesity comparing CK-0045 with Placebo (2 arms). Primary endpoint: Change from baseline in area under the plasma glucose curve after a mixed-meal tolerance test (AUCPG0-4h) after 16 weeks of treatment. Started Sep 2024; status: completed.
02
Drugs
CK-0045
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on 2024-514191-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514191-41-00.